NOTICE OF ALLOWANCE - ISSUED
issued
on 12 Nov 2024
Last Applicant/ Owned by
1801 Main Street, Suite 1300
Houston
TX
770028121
Serial Number
98263879 filed on 09th Nov 2023
Registration Number
N/A
Correspondent Address
Karen Won
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
REVIVE, RENEW, PREVENT, AND PROTECT
Research and development in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Providing medical scientific research information in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and dege Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Research and development in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Providing medical scientific research information in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceutical and biological preparations for respiratory diseases and disorders; Pharmaceutical and biological preparations for use in pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing cancer, fibrotic diseases, NASH, Crohn's Disease, osteoarthritis, viral infections, and hepatitis C; Pharmaceutical and biological preparations for improving air flow obstruction, reduce neutrophils and secreted elastase, improve mucociliary clearance, increase lung cell viability, increase alveolar regeneration, reduce smooth muscle proliferation, regulate cartilage destruction, reduce inflammation; Therapeutic agents in the nature of nebulized peptides, monoclonal antibodies, and recombinant protein domains for reversing underlying mechanisms of COPD
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 98263879
Mark Type
No Service Mark
Attorney Docket Number
No 063517-400
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 12th Nov 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 17th Sep 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 17th Sep 2024 | PUBLISHED FOR OPPOSITION |
| 28th Aug 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 14th Aug 2024 | EXAMINERS AMENDMENT E-MAILED |
| 14th Aug 2024 | EXAMINERS AMENDMENT -WRITTEN |
| 14th Aug 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| 14th Aug 2024 | EXAMINER'S AMENDMENT ENTERED |
| 14th Aug 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 04th Jul 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |